In the adult, involvement of bone marrow-derived circulating endothelial progenitor cells (EPCs) in tissue revascularization (vasculogenesis) and the cooperation of hematopoietic cell subsets in supporting this process have been described in different experimental animal models. However, the effective contribution of such cells in restoring organ vascularization in a clinical setting needs to be clarified. In this study, a mouse transplantation model was engrafted by human cord blood hematopoietic stem and progenitor cells to follow the behavior of donor-derived endothelial and hematopoietic cells in the presence of a localized source of an angiogenic inducer. Human endothelial markers (CD31   +   /CD45 -, VE-cadherin + ) were always detectable in the bone marrow of transplanted mice, while they were only randomly detectable in peripheral neovascularization sites. To investigate the ability of human transplanted hematopoietic stem cells to support new vessel formation in response to altered homeostatic conditions, chimeric mice were further treated by systemic injection of human mononuclear cells (MNCs). Our data indicate that MNC administration in transplanted mice enhances vasculogenesis in the newly formed vessels. Taken together these results suggest that human-derived EPCs, long-term engrafting a xenotransplantation model, have hematopoietic and endothelial developmental potential, which can be modulated by altering the physiological conditions of host microenvironment.
been shown to contain a large number of HSCs, with higher proliferative capacity, compared with adult BM (3) . Among progenitor cells in the BM, a small population known as endothelial progenitor cells (EPCs) can be mobilized into the circulation, giving rise to circulating endothelial progenitors (CEPs) and contributing to angiogenesis associated pathological settings. The discovery of EPCs has led to the notion of adult vasculogenesis, in which BM-derived EPCs are recruited to target organs, where they contribute to neovascularization in situ (4, 5) . Many studies have shown incorporation of BM-derived cells into newly formed vessels during wound healing and limb ischemia (6) (7) (8) (9) (10) (11) (12) (13) (14) , postmyocardial infarction (15) (16) (17) , endothelialization of vascular graft (18) (19) (20) , atherosclerosis (21), retinopathies (22), and tumor growth (23). Vascular trauma, organ regeneration, and injury result in the release of chemokines and angiogenic factors that favor the mobilization of EPCs from bone marrow through a matrix-metalloproteinase-9 (MMP-9)-dependent mechanism (24-27). The subsequent rise of CEPs is followed by their recruitment to the site of neovascularization, where they accelerate the vascular healing process. Emerging evidence suggests that angiogenic factors, including vascular endothelial growth factor (VEGF)-A, also promote mobilization and recruitment of proangiogenic hematopoietic cell subpopulations. Comobilization of proangiogenic VEGF-R1 + hematopoietic stem and progenitor cells, such as VEGF-R1 + myeloid cells, may facilitate functional incorporation of VEGF-R2 + EPCs into neovessels (28, 29). However, the mechanism by which various subsets of hematopoietic cells contribute to the initiation and maintenance of neoangiogenesis needs to be investigated.
BM-derived progenitors are, beyond doubt, involved in experimental tissue revascularization. However the importance of such cells in restoring organ vascularization in a clinical setting remains unknown. Also, the relative contribution and the potential cooperation between EPCs, CEPs, and hematopoietic cells to revascularization process need to be clarified.
In the present study, the contribution of human HSCs to the formation of endothelium-lined vasculature was assessed in vivo, using a long-term xenotransplantation model. To investigate the development and differentiation of human HSCs following transplantation, NOD/SCID mice were used as recipients, since they are a suitable model for achieving high levels of human engraftment and for preclinical analysis of stem cell activity (30). Human CB stem cell transplantation in immunodeficient mice results in repopulation of the BM with clonogenic progenitors, which supports development of erythroid, myeloid, and B cell lineages (31, 32). It has been reported that CB-derived hematopoietic stem cells, engrafted in the BM of NOD/SCID mice, generated T cell and elements of the endothelial cell lineage, capable of homing to and developing within a human thymic graft transplanted at distant sites (33). To investigate the contribution of human transplanted hematopoietic and endothelial progenitors in neovascularization process during adult life, NOD/SCID mice engrafted with human cord blood CB-CD34 + progenitor cells were used in a Matrigel implantation assay, which is a wellestablished neovascularization assay in response to angiogenic growth factors (34). The behavior of both human hematopoietic and endothelial cells was monitored in BMs and neovascularization sites of xenotransplanted mice.
METHODS

Human cells
Umbilical CB was obtained at the end of full-term pregnancies, after clamping and cutting of the cord, by drainage of blood into sterile collection tubes containing the anticoagulant citratephosphate dextrose. Peripheral blood was obtained from healthy donors after informed consent.
CD34 + cell purification
Mononuclear cells (MNC) were isolated from CB using Ficoll Lymphoprep (density, 1077; Oslo, Norway) density centrifugation. The CD34 + MNC fraction was isolated with superparamagnetic microbead selection using high-gradient magnetic field and miniMACS column (Miltenyi Biotech, Gladbach, Germany). The efficiency of the purification was verified by flow cytometry counterstaining with a CD34-phycoerythrin (PE; HPCA-2; Becton Dickinson, San Jose, CA) monoclonal antibody (MoAb). In the cell fraction containing purified cells, the percentage of CD34 + cells ranged from 85 to 98%.
MNC cell separation
Mononuclear cells (MNC) were isolated from peripheral blood using Ficoll Lymphoprep (density, 1077; Oslo, Norway) density centrifugation, washed twice in phosphate buffered saline (PBS) and resuspended in PBS.
Lentivirus production and infection
Replication-defective self-inactivating HIV-1 vectors were constructed as described (35-37). Plasmids were the transfer vector pRRLsin.PPT.hPGK.EGFP.Wpre, encoding the enhanced green fluorescent protein (EGFP) the VSV-G envelope-encoding plasmid pMD.G, and the packaging plasmid CMVR8.74. Vectors were produced by transient-3 plasmid transfection of 293T cells. Viral supernatants were concentrated by ultracentrifugation. Titers of vector preparations were determined by transduction of HeLa cells with serial dilutions of vector supernatants, followed by cytometric analysis 3 days later. Transduction of CD34 + progenitor cells or MNCs with lentiviral vectors was carried out as described by Piacibello and co-workers. (38).
Animals
NOD/LtSz scid/scid (NOD/SCID) mice were obtained from Jackson Laboratories (Bar Harbor, ME) and maintained in the animal facilities of Centro di Immunogenetica ed Oncologia Sperimentale (CIOS; Torino, Italy). Mice that were to receive transplants were irradiated at 6 to 8 weeks of age with 350 cGy total body irradiation from a 137 Cs source and, 24 h later, given a single intravenous injection of 0.8×10 6 human CD34 + CB cells fresh or harvested after transduction, as described. After 6 weeks Matrigel (BD Bioscience) was injected subcutaneously and 10 days later mice were killed for analysis of human cells. Some nontransplanted mice were inoculated with Matrigel matrix and the day after injected with 0.8×10 6 human CD34 + CB cells into the tail vein. In some experiments, the day after the Matrigel implantation, engrafted mice were injected in the tail vein with 5×10 5 MNCs purified from peripheral blood.
Matrigel plug assay
Matrigel (BD Biosciences) was mixed with 100ng/ml VEGF-A 165 (R&D Systems) and 64U/ml heparin (Sigma-Aldrich). The Matrigel mixture (500 µl) was injected subcutaneously in the ventral region of 6-week transplanted mice, after 8-day mice were killed and the Matrigel plugs were removed and split in two parts; one portion was directly lysed in Tryzol for molecular analysis, while the other was frozen and used for immunofluorescence assays.
Immunophenotyping by flow cytometry
Flow cytometric evaluation of CD34 + purification
After purification, aliquots of CD34 + CB cells were incubated with human immunoglobulin G (IgG; Fluka, Gallarate, Milano, Italy) and then stained for 30 min with anti-CD34-phycoerythrin (PE; Becton Dickinson, San Jose, CA) and anti-CD38-fluorescein isothiocyanate (FITC; Dako A/S, Glostrup, Denmark) MoAb or the corresponding control antibodies in fluorescenceactivated cell sorter (FACS) buffer containing PBS, 0.1% bovine serum albumin (BSA; Sigma Aldrich Italy), and 0.01% sodium azide (NaN 3 ). Cells were then washed and fixed in PBS containing 2% paraformaldehyde (Farmitalia S.p.A., Milan).
Flow cytometric detection of human cells in murine tissues
BM cells were flushed from the femurs and tibias of each mouse using a syringe and a 26-gauge needle. Cells were then resuspended at 2×10 6 cells/ml and incubated with mouse and human IgG (Fluka Chemika Biochemika, Buchs, Switzerland) to block nonspecific binding to Fc receptor. Cells were then incubated with MoAbs specific for human CD45, human CD34, human CD38, human CD14, human CD41, human CD19, human glycophorin-A (GpA) and directly labeled with FITC or PE (Dako A/S, Glostrup, Denmark) for 30 min at 4°C. Some cells from each suspension were similarly incubated with irrelevant (control) MoAbs labeled with FITC or PE. To prepare cells for flow cytometry, contaminating red blood cells were lysed with 8.3% ammonium chloride and the remaining cells were then washed in PBS with 0.1% BSA, 0.01% NaN 3 . Cells were then washed and fixed. Cells from unmanipulated NOD/SCID mice were stained with each of the human specific MoAbs and used as negative controls. Only levels of fluorescence that excluded 99.9% of all of these negative controls were considered as specific. Flow cytometric analysis was performed using a FACSVantage cytometer (Becton Dickinson, Co, USA) and Cell Quest software. At least 10,000 events were acquired for each analysis.
DNA and RNA extraction
High-molecular-weight DNA was extracted from 1x10 6 BM and Matrigel plug cells derived from engrafted mice by lysis in 500µl of proteinase K buffer (0.01M Tris-HCl, pH 7.4, 0.15M NaCl, 0.01M EDTA, pH 8.0, 0.01% sodium dodecyl sulfate) with 30µg of proteinase K (Gibco) for 2h at 56°C. One extraction with 500µl of buffered phenol/chloroform/isoamyl alcohol (25:24:1) was then performed. DNA was precipitated by addition of (1M) NH 4 Ac and 2 volume of absolute ethanol and then resuspended in 10mM Tris-HCl, 1mM EDTA pH 8 (TE buffer).
RNA was extracted from 1×10
6 BM or Matrigel plug cells by lysing in 1 ml of Trizol (Invitrogen, Ltd, United Kingdom) using specimen's protocol.
Reverse transcriptase-polymerase chain reaction analysis
Retrotranscription was carried out on total RNA (50 ng) using random hexamers according to Superscript kit specimens (Invitrogen). Primers for specific hematopoietic and endothelial differentiation markers were designed on different exons (except EGFP) to amplify human or murine sequences. The following primers were used: murine CD31 forward CCAGCTGCTCGACTTCTGAA and reverse GCACTGCCTTGACTGTCTTA (300bp product), human CD31 forward CCAGCAGTACCACTTCTGAA and reverse GCATCTGGCCTTGCTGTCTA (316 bp product), human VEcadherin forward TGATGCTCCTCGCCACAT and reverse CATACCTGGCCTGCTTCTCT (658bp product), human CD11 forward CGGCTGAACCAGACTGTCTCATA and reverse ACCTCGAACGGCTCCACTTT (379bp cDNA product, 1338bp gDNA product), GAPDH forward ACCACAGTCCATGCCATCAC and reverse TCCACCACCCTGTTGCTGTAG (452bp cDNA product, 555bp gDNA product), and EGFP forward GCTGGACGGCGACGTAAAC and reverse CCATGTGATCGCGCTCTC (604bp product).
Southern blot
After electrophoresis on agarose gel and transfer to nylon membrane, PCR products were hybridized with the Rapid-hyb Buffer (Amersham Pharmacia Biotech, Italy) with 32 P-labeled primers. Oligonucleotides (5 pmol) were labeled with [
32 P] adenosine 5′-triphosphate (ATP) 5000 Ci/mn (185 Bq/mn) (Amersham Pharmacia Biotech), using 20 U T4 polynucleotide kinase (New England BioLabs, Celbio, Italy) at 37°C for 1 h.
Immunofluorescence on cryostatic sections
Matrigel plugs were embedded in frozen section medium Killik (Bio Optica Italy) and quickly frozen in liquid nitrogen. Cryostatic sections (5 µm thick) were fixed with dimethylformaldehyde, washed in water and then blocked with 10% goat serum (DAKO) in PBS containing 0.5% bovine serum albumin (BSA). After primary antibodies incubation for 1 h at room temperature, sections were washed and stained with secondary antibodies for 30 min at room temperature. Cell nuclei were stained using DAPI (1 µg/100 ml PBS) and then after being washed, slides were mounted using Fluorescent Mounting Medium (DAKO). The following primary antibodies were used: mouse α-humanCD31 (DAKO; JC/70); rat α-murine CD31 (BD; MEC13.3); mouse α-human CD11b (DAKO; 2LPM19C); rabbit α-murine; and human Von Willebrand Factor (VWF) (DAKO). Secondary antibodies used: tetramethyl rhodamine
To quantify the contribution of human-derived cells to neovascularization, Matrigel slices were double stained using the MoAb α human CD31 and αVWF. Human and murine capillaries with a patent lumen and endothelial cell clusters with three or more cells were counted.
RESULTS
Human hematopoietic and endothelial cell engraftment in the BMs of CB cell-transplanted mice
To study the fate of HSC-derived cells in vivo and their role in new blood vessel formation, we used a long-term transplantation model in which it is possible to discriminate the origin of the cells contributing to the development of new capillaries. NOD/SCID mice were sublethally irradiated and intravenous injected with human CD34 + cells purified from cord blood. Six weeks after CB cell transplantation the engrafted mice were implanted subcutaneously with VEGF-A 165 -enriched Matrigel plugs. Ten days later, mice were killed and BM and Matrigel plugs were recovered.
Transplantation of human CD34
+ CB cells resulted in high levels of hematopoietic cell engraftment in NOD/SCID mice (CB cell mice, n=20 evaluated in three different experiments), being up to 75% of human CD45 + cells detected in the BM of animals (Fig. 1A) . Flow cytometry analysis demonstrated the differentiation of human CD34 + CB cells toward both lymphoid and myeloid lineages (Fig. 1B) as previously reported (31). A well-represented human CD31 + cell population (Fig. 1C) was also detected in the BM of CB-mice. The human CD31 + population contained both CD45 + hematopoietic cells and CD45 -endothelial cells (Fig. 1D) , and the CD31 + /CD45
-endothelial subpopulation represented ~3.5% of total BM cells. RT-PCR analysis of RNA isolated from the BMs of engrafted mice confirmed the presence of cells expressing the human-endothelial specific marker VE-cadherin and CD31 (Fig. 1E ).
Human cells localize to the neovascularization sites of CB mice
To follow the localization of donor-derived cells, in some experiments before transplantation, the human CD34 + cells were transduced by a lentiviral-EGFP expression vector. In all the BMs of mice transplanted with EGFP-CD34 + cells (n=6) the expression of the transgene was evident. To analyze the level of human hematopoietic engraftment on mice transplanted with EGFP-CD34 + CB cells, murine BM cells were stained with human-specific MoAb against the leukocyte common antigen CD45. FACS analysis revealed high levels of human engraftment ( Fig. 2A) . Human lymphoid, myeloid, and endothelial EGFP + subpopulations were found by flow cytometry in the BM of animals (data not shown). PCR analysis of genomic DNA isolated from the Matrigel plugs of engrafted mice also established the presence of cells carrying the EGFP transgene, demonstrating the localization of human donor cells to these sites (Fig. 2B) .
Human endothelial and hematopoietic cells in Matrigel implants of CB-mice
To determine whether donor-derived cells incorporated into vascular structures formed in Matrigel plugs, exhibited features of endothelial cells, we performed RT-PCR and immunohistochemical analysis. Screening for human and mouse CD31 expression was performed by RT-PCR on Matrigel invading cells using species-specific primers. The Matrigel plugs, that were established positive for the expression of human CD31 by RT-PCR (Fig. 3A) , were subsequently investigated by immunohistochemistry to confirm the presence of human endothelial cells lining the nascent capillaries. Sections of Matrigel plugs were stained with antibodies raised against human and mouse CD31, VWF, and HLA class I. Most of the capillaries were largely of murine origin, as demonstrated by the costaining with antibodies to mouse CD31 and VWF (Fig. 3B) (Fig. 3A, 3D ). To determine the ability of cord blood endothelial and myeloid progenitors to home directly to the neovascularization site, we attempted to establish the Matrigel plug first in irradiated NOD/SCID mice and then inject CB CD34 + cells. Six animals were tested in two different experiments injecting the same number of CB CD34 + cells used for the long-term transplantation and all the Matrigel plugs resulted negative for the human markers CD31 and CD11b. This data indicate that in our experimental conditions CB CD34 + cells do not localize preferentially to these sites before residence in the marrow. These results suggest that in the proposed model, vasculogenesis occurred, but its contribution to capillary formation was not very significant. Certainly, the transplanted HSCs seemed to contribute to Matrigel plug cellularity more to supply myelo-monocytic cells (CD11b + and CD31+/VWF -) than ECs (CD31 + /VWF + ).
Enhanced vasculogenesis in transplanted NOD/SCID mice following MNC injection
In several animal models it has been reported that microenvironment perturbation following administration of recombinant cytokines or allogenic cells (12, (39) (40) (41) ameliorates the incorporation of EPCs at sites of neovascular formation. Therefore, we looked at the role of conditions altering host microenvironment on the ability of transplanted endothelial progenitors to support vasculogenesis. Mice engrafted with CB-derived progenitors were intravenously injected with MNCs separated from human peripheral blood one day after Matrigel implantation.
To discriminate human long-term CB-repopulating cells from human peripheral blood MNCs, these latter were transduced using a lentiviral-EGFP expression vector, sorted by FACS (90-95% purity) and injected in mice. The incorporation of human-derived endothelial cells (CD31 + /VWF + ) into neovascularization sites of Matrigel plugs was detectable in 44% of "transplanted and MNC-injected" mice (MNC/CB, n=18) vs. 25% in "only transplanted" (CB) mice (Fig. 4A, 4B, 4C ). The number of capillaries containing human endothelial cells was evaluated in plugs of CB/MNC-mice (n=3), for which the number of capillaries increased considerably (Table 1) in comparison to plugs of CB-mice (n=3). Matrigel plugs of control mice, not transplanted but injected with human MNCs, were all negative for expression of human CD31. Moreover, PCR analysis performed on genomic DNA of Matrigel plug cells of CB/MNCmice injected with EGFP-transduced MNC (n=6) resulted negative for EGFP insertion, indicating that injected MNCs did not localize preferentially into Matrigel implants, and their influence on Matrigel vascularization could probably be mediated by soluble factors.
DISCUSSION
In this study, the behavior of human long-term repopulating progenitors in neovascularization processes during adult life was investigated in vivo. To simulate clinical settings as far as possible and to reduce radiation-induced tissue damage, the animals were sublethally irradiated before HSC transplantation. Moreover, the performed vasculogenic assay, which consisted in s.c. implantation of Matrigel plugs enriched by angiogenic inducers, was not as aggressive as the acute injury models (8, 12, 15-17, 21, 23) . Under these experimental conditions, engraftment of both human hematopoietic and endothelial cells could be visualized in CB transplanted NOD/SCID mice. Transplantation of CD34 + CB cells resulted in subsequent lymphomyeloid reconstitution and the majority of human cells generated in mice grafted with CB cells belonged to the B-lymphoid lineage, in agreement to previously published data (31, 32). The CD34 + EPCs have been successfully cultured and in vitro differentiated from CD34 + -enriched peripheral blood cells by Ashara and co-workers. These differentiated cells expressed endothelial cell markers (CD31, VEGF-receptor2/flk-1, and VWF), were able to form capillary-like structures in in vitro angiogenic assays and to incorporate into regenerating endothelial lesions in vivo as shown after injection into mouse and rabbit models (7). It was likely that this cell population or its progeny also developed in our long-term xeno-transplantation model. Our results demonstrate that a human population showing endothelial features reside in the mouse BM after transplantation of CB-derived CD34 + cells and that this cell population always engraft in NOD/SCID mice, as indicated by the detection of human CD31 + /CD45
-and human VEcadherin + populations in all BM of transplanted mice.
Further, we show that following CB CD34 + transplantation, human endothelial progenitor cells contained in hematopoietic stem cell grafts can be incorporated at low levels, into new blood vessels of implanted Matrigel plugs simply containing an angiogenic inducer. The mouse treatment with human mononuclear cells greatly enhanced the incorporation of human cells into nascent vessels in the plug, suggesting that a perturbation of homeostatic conditions is necessary for the positive modulation of the angiogenic response. The enhanced vasculogenesis observed after human MNC injection could be mediated by secreted factors. This is suggested by the absence of these injected cells into the Matrigel plugs. Hematopoietic cells release angiogenic factors, including VEGF-A (42, 43), VEGF-C (44) angiopoietin-1 (45) and matrixmetalloproteinase (24), which have been described to affect EPCs mobilization from BM. A possible mechanism underlying the enhanced vasculogenesis observed in our model following MNC administration, involves cytokine-induced mobilization of human EPCs from BM to neovascularization peripheral sites.
Our results are in agreement with the recent observation that contribution in vascular formation of the BM-derived cells may depend on severity of the vascular injury (46) . Actually, the current models describing the contribution of BM vasculogenesis in organ vascularization are characterized by a severe injury or shock for the recipient animal (8, 10, 12, 33) . Human EPCs contributing to retina neovascularization after laser photocoagulation have been reported in a murine long-term xenotransplantation model, similar to that described here. The range of human cells incorporated into neovessels was comparable to that observed in our model after MNC injection (47) .
The low frequency of human EPCs' incorporation into newly formed capillaries observed in our model in the absence of MNC injection could reflect angiogenic factors contained in the Matrigel matrix could be just sufficient to recruit circulating EPCs. In physiological conditions, EPCs represent a small proportion of total circulating cells (8, 12) . Our findings are consistent with recent reports that questioned the proposed major role and the biological significance of BMderived EPCs in tissue revascularization (17, 48, 49) . The variation in mechanical or biophysical properties inherent to a specific vascular locus, the absence or presence of inflammatory stimuli, and the unique microenvironment within different organ beds, all may significantly affect the recruitment of circulating EPCs, thereby explaining the apparent differences in the contribution from the BM.
Our data also indicate that a human population of myelomonocytic origin is localized into Matrigel of CB-transplanted NOD/SCID mice. This graft-derived population could cooperate to sustain neovascularization processes. BM-derived monocytes have been shown to exert a crucial role in some model of tumor angiogenesis, probably by producing angiogenic factors (50) (51) (52) , and, in human tumors, monocyte infiltration has been correlated with invasion and angiogenesis (29).
Taken together, these results indicate that human CB-derived EPCs, long-term engrafting a xenotransplantation model, have hematopoietic and endothelial developmental potential, which can be modulated by perturbing the homeostatic conditions of the host microenvironment. Better knowledge of the mechanisms regulating mobilization, homing, and differentiation of HSC and EPCs to new vessels, is needed to indicate new therapeutic applications in many different fields spacing from cardiovascular diseases to tumor angiogenesis. Our long-term transplantation model allows further treatments of mice by systemic injection of cells during and after the time of engraftment. Therefore it is suitable for studying the role of different leukocyte subpopulations or mediators in modulating vessel formation. The genomic DNA from the Matrigel plug cells of the above mice was amplified by PCR for the EGFP insertion, and for the human/murine GAPDH gene as positive control for DNA integrity. The EGFP-PCR products were separated on agarose gel, blotted on nitrocellulose filter, and visualized using radio-labeled primers, while the GAPDH-PCR products, after electrophoresis on agarose gel, were visualized with ethidium bromide. Negative controls, genomic DNA from a nontransplanted mouse (lane 1) and from a mouse (lane 2) that has been transplanted with nontransduced CD34 + cells. EGFP + cells were detectable in all plugs of mice that have been transplanted with EGFP-transduced CD34 + cells (lanes 3-8) . 14-20, n=7) or nontransplanted mice (lanes 12-13, n=2 ) and retrotranscripted as indicated in the "Methods." The cDNA was analyzed for the presence of transcripts for human CD31 and human CD11b, and human/murine GAPDH as positive control for cDNA integrity, as detailed in the legend of 
